Ruth Ann Vleugels, MD, MPH, MBA

An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.

Patient Communication and Utilization of JAK Inhibitors in Atopic Dermatitis

Video content above is prompted by the following questions:

How do you educate and counsel patients who want to consider or are currently using a JAK inhibitor?

How do you discuss treatment targets and manage patient expectations?

What suggestions do you have for patients and healthcare professionals to optimize treatment of AD with JAK inhibitors?


Videos

An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.

Safety Data of Oral JAK Inhibitors in Atopic Dermatitis

Are there differences in safety data from clinical trials vs. real-world studies? What has been your clinical experience with abrocitinib and upadacitinib?

Discuss your monitoring schedule for patients taking JAK inhibitors.

How do you modify your monitoring protocol according to patient characteristics and preferences?


Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.

Choosing Between Oral JAK Inhibitors in Atopic Dermatitis

How do you choose between different JAK inhibitors? What role do efficacy and safety data play in your selection?

What are important considerations when choosing a JAK inhibitor in specific patient populations (e.g., older adults ≥65 yr)?


An expert on atopic dermatitis identifies patients who are good candidates for JAK inhibitors, highlighting contraindications for treatment.

Candidates for Oral JAK Inhibitor Use in Atopic Dermatitis

Who is/is not a good candidate for JAK inhibitor?

What findings would you consider to be absolute or relative contraindications for JAK inhibitor use in AD?

Ruth Ann Vleugels, MD, MPH, MBA

Articles